Abstract
With over 16.8 million rare disease patients in China, there is an urgent need for data-driven policy to address their unmet needs. This study utilized a comprehensive questionnaire-based approach to analyze the status quo of 1,959 patients and caregivers across 104 rare diseases. Findings reveal significant diagnostic delays, extreme geographic inequality in medical resources, and a heavy socioeconomic and psychological burden. Standardized health assessments (SF-36, PHQ-9, etc.) showed significantly poorer health and mental well-being compared to healthy populations. The study recommends legislative action, such as an Orphan Drug Act, to improve awareness and support for this community.
Introduction
Rare diseases affect an estimated 6–10% of the global population. In China, the absence of a formal legal definition and specific legislation for rare diseases has left millions of patients in a precarious position. This study addresses the critical data gap regarding the "diagnostic odyssey," financial insolvency, and psychological health of these individuals and their families to provide an empirical basis for future legislation regarding orphan drug development and medical insurance.
Methods and Participants
The researchers conducted a cross-sectional study using a 116-question survey distributed between March and May 2020. The cohort included 1,959 participants representing 104 rare diseases, including Congenital Adrenal Hyperplasia (CAH), Phenylketonuria (PKU), and Hemophilia.
The study employed five validated clinical instruments: SF-36 (general health), PHQ-9 (depression), PHQ-15 (somatic symptoms), GAD-7 (anxiety), and PSQI (sleep quality). Data were analyzed using a General Linear Model (GLM) to identify key predictors of health outcomes.
Key Insights
Geographic Inequality and the "Big City" Bottleneck
A primary finding was the extreme centralization of medical expertise. Nearly 44% of diagnoses occurred in just 10 hospitals, and 42% were concentrated in five major cities. This geographic disparity forces patients from rural provinces to travel vast distances, often at great expense, to receive specialized care.
The Newborn Screening Advantage
Contrary to the 5–7 year diagnostic delay often reported in Western literature, this cohort experienced an average delay of 1.4 years. This improvement is largely attributed to China's expanding newborn screening programs, which identified 26.1% of the cases in this study.
Key Results: Health and Socioeconomic Impact
The psychological and physical toll on both patients and caregivers is severe. Patients reported moderate depression (PHQ-9 average of 12.1) and mild-to-moderate anxiety (GAD-7 average of 9.0), compared to healthy normative values of approximately 3.0.
As shown in the table above, patients scored significantly lower across all SF-36 domains—particularly in "Role Physical" (26.8) and "Social Functioning" (33.3)—compared to healthy benchmarks. Caregivers also exhibited higher-than-normal levels of distress, highlighting that a rare disease is a "family diagnosis."
Socioeconomically, the burden is equally heavy. Over 12% of families spent more than their entire annual income on medical costs, and nearly half (48.1%) had no insurance coverage for their specific disease. Furthermore, only 4.7% of patients held full-time employment, and nearly 60% faced significant barriers to education.
Conclusion and Recommendations
The study identifies a lack of awareness and legislative support as the primary challenges facing the rare disease community in China. The authors call for the establishment of a National Rare Disease Registry and the urgent passage of an Orphan Drug Act to incentivize local R&D and improve the affordability of life-saving treatments. Addressing these systemic issues is essential to protecting the rights and health of millions of citizens.
Summary updated